Institute of Pharmacy, Nirma University, Ahmedabad, India.
Institute of Pharmacy, Nirma University, Ahmedabad, India.
Eur J Pharmacol. 2021 Feb 15;893:173805. doi: 10.1016/j.ejphar.2020.173805. Epub 2021 Jan 1.
Colon cancer is a major health issue and number of cases are increasing every year. Diabetes mellitus is also a significant health issue that is growing day by day worldwide having negative influences on the survival of individuals. Research has shown a strong relationship between the two malignant diseases. The risk of colon cancer with patients who have type 2 diabetes mellitus has spiked by 30%. The scientific research suggests insulin has a major role in the spread of cancer and the condition unifying between the two diseases is hyperinsulinemia. Several anti-diabetic agents are used for the treatment of type 2 diabetesmellitus. However, their mechanism of action against cancer activity is a question and only a few agents have shown positive signs of action in colon cancer associated with type 2 diabetesmellitus. Hence, the identification of targets, which is common for both colon cancer, associated with type 2 diabetesmellitus has become an urgent requirement. Novel targets such as Liver X receptors, Histone deacetylase inhibitors (HDACi), Glucose Transporters (GLUTs), Peroxisome proliferator activator receptors (PPARs), Dipeptidyl peptidase-IV inhibitors (DPP4i), Cyclin-dependent kinase 4 inhibitors (CDK4i), Estrogen receptors,Mechanistic target of rapamycin (mTOR), Insulin-like growth factor receptors (IGF) are some of the targets which are common for both, type 2 diabetesmellitus and colon cancer. This current review gives an overview of the targets (using one worm) which are common for both viz. diabetes mellitus and colon cancer (two fish).
结肠癌是一个主要的健康问题，每年的病例数都在增加。糖尿病也是一个严重的健康问题，在全球范围内每天都在增加，对个体的生存产生负面影响。研究表明，这两种恶性疾病之间存在很强的关联性。患有 2 型糖尿病的结肠癌患者的风险增加了 30%。研究表明，胰岛素在癌症的扩散中起着重要作用，两种疾病之间的共同条件是高胰岛素血症。有几种抗糖尿病药物用于治疗 2 型糖尿病。然而，它们对癌症活性的作用机制是一个问题，只有少数几种药物在与 2 型糖尿病相关的结肠癌中显示出积极的作用迹象。因此，确定与 2 型糖尿病相关的结肠癌的共同靶点已成为当务之急。新的靶点，如肝 X 受体、组蛋白去乙酰化酶抑制剂（HDACi）、葡萄糖转运蛋白（GLUTs）、过氧化物酶体增殖物激活受体（PPARs）、二肽基肽酶-4 抑制剂（DPP4i）、细胞周期蛋白依赖性激酶 4 抑制剂（CDK4i）、雌激素受体、雷帕霉素的机制靶点 (mTOR)、胰岛素样生长因子受体 (IGF) 是一些与 2 型糖尿病和结肠癌都相关的共同靶点。这篇综述概述了与 2 型糖尿病和结肠癌都相关的靶点（使用一种线虫），即糖尿病和结肠癌（两种鱼类）。
